1-8 of 8
Renhua Guo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer

Available to Purchase
Tianyu Qu, Lei Song, Jiali Xu, Xiyi Lu, Dandan Yin, Jiali Dai, Chen Zhang, Renhua Guo, Erbao Zhang
Journal: Cancer Research
Cancer Res (2025)
https://doi.org/10.1158/0008-5472.CAN-23-3748
Published: 14 May 2025
View articletitled, MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer
Open the PDF for MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract CT053: Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2)

Free
Shun Lu, Jie Hu, Jianhua Chen, Yan Yu, Xiangjiao Meng, Xiaorong Dong, Yanping Hu, Yinghua Ji, Ying Cheng, Weibo Wang, Fangling Ning, Zhihong Zhang, Zhiye Zhang, Chunling Liu, Qiming Wang, Wei Zheng, Xiujuan Qu, Honghai Wang, Runxiang Yang, Renhua Guo, Jianhua Shi, Feng Wu, Dongqing Lv, Jian Fang, Zhi Xu, Huaqiu Shi, Haichuan Su, Yongxing Chen, Cheng zhi Zhou, Junhong Zhang, Xuewen Liu, Zhaoxia Dai, Wen Li, Zili Meng, Guojun Zhang, Biyong Ren, Lin Wu, Yalun Li, Xinmin Yu, Ziping Wang, Jian Feng, Yueyin Pan, Juan Li, Xiangdong Zhou, Suxian Hu, Tongmei Zhang, Laiyu Liu, Jiming Shen, Shaonan Fan, Zhenming Chen
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT053.
https://doi.org/10.1158/1538-7445.AM2025-CT053
Published: 25 April 2025
View articletitled, Abstract CT053: Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2)
Journal Articles

Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)

Free
Ying Cheng, Xiqin Zhang, Lin Wu, Wenxiang Wang, Wenqun Xing, Chunling Liu, Caigang Liu, Kai Chen, Jianhua Shi, Peng Zhang, Shidong Xu, Xiaodong Zhang, Xiaorong Dong, Haohui Fang, Xinmin Yu, Yang Gao, Gaofeng Li, Liang Chen, Huiyuan Gong, Renhua Guo, Zhenyuan Gao, Yinghua Ji, Lunxu Liu, Xianling Liu, Hui Tian, Fei Xiong, Xin Zhao, Lejie Cao, Qing Geng, Hongxu Liu, Jixian Liu, Li Yang, Zhenfa Zhang, Di Ge, Xingya Li, Minghui Wang, Yan Xu, Zhi Xu, Jun Chen, Zhaoxia Dai, Jian Hu, Juan Li, Shujun Li, Min Ye, Aimin Zang, Chanjuan Xie, Zhenzhong Su, Zhenmin Chen, Shaonan Fan
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT126.
https://doi.org/10.1158/1538-7445.AM2025-CT126
Published: 25 April 2025
View articletitled, Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)
Journal Articles

MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer

Available to Purchase
Qingqing Zhu, Chongguo Zhang, Tianyu Qu, Xiyi Lu, Xuezhi He, Wei Li, Dandan Yin, Liang Han, Renhua Guo, Erbao Zhang
Journal: Cancer Research
Cancer Res (2022) 82 (23): 4340–4358.
https://doi.org/10.1158/0008-5472.CAN-22-1289
Published: 02 December 2022
View articletitled, MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer
Open the PDF for MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract 5087: KDR mutation as novel biomarker for immune checkpoint inhibitors in pan-cancer

Free
Renhua Guo, Yanan Cui, Pengpeng Zhang, Xiao Liang, Jiali Xu, Xinyin Liu, Yuemin Wu, Wei Wang, Fang Zhang, Junling Zhang, Mengli Huang
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5087.
https://doi.org/10.1158/1538-7445.AM2022-5087
Published: 15 June 2022
View articletitled, Abstract 5087: KDR mutation as novel biomarker for immune checkpoint inhibitors in pan-cancer
Journal Articles

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Free
Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Ying Cheng, Gang Wu, Peiguo Cao, Dongqing Lv, Xiangming Jin, Hong Jian, Chengshui Chen, Guanming Jiang, Panwen Tian, Kai Wang, Hui Zhao, Gongyan Chen, Qun Chen, Cuimin Ding, Junquan Yang, Renhua Guo, Guoping Sun, Bin Wang, Liyan Jiang, Wu Zhuang, Zhe Liu, Jian Fang, Yunpeng Liu, Jian Zhang, Jun Chen, Yueyin Pan, Qitao Yu, Min Zhao, Jiuwei Cui, Dianming Li, Tienan Yi, Zhuang Yu, Yan Yang, Yan Zhang, Xiuyi Zhi, Yunchao Huang, Rong Wu, Liangan Chen, Aimin Zang, Lejie Cao, Qingshan Li, Xiaoling Li, Yong Song, Donglin Wang, Shucai Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT170.
https://doi.org/10.1158/1538-7445.AM2021-CT170
Published: 01 July 2021
View articletitled, Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
Journal Articles

Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations

Free
Jinji Yang, Qing Zhou, Huajun Chen, Lin Wu, Jun Zhao, Renhua Guo, Yun Fan, Hepeng Shi, Weizhe Xue, Peilong Zhang, Han-Zhang Han, Xuan Lin, Shuyin Chen, Lu Zhang, Hao Liu, Xinru Mao, Bin Gan, Yilong Wu
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT127.
https://doi.org/10.1158/1538-7445.AM2020-CT127
Published: 15 August 2020
View articletitled, Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations
Journal Articles

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Free
Shun Lu, Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng-Ta Yang, Yong Song, Gee-Chen Chang, You Lu, Hongming Pan, Chao-Hua Chiu, Zhehai Wang, Jifeng Feng, Jianying Zhou, Xingxiang Xu, Renhua Guo, Jianhua Chen, Haihua Yang, Yuan Chen, Zhuang Yu, Her-Shyong Shiah, Chin-Chou Wang, Nong Yang, Jian Fang, Ping Wang, Kai Wang, Yanping Hu, Jianxing He, Ziping Wang, Jianhua Shi, Shaoshui Chen, Qiong Wu, Changan Sun, Chuan Li, Hongying Wei, Ying Cheng, Wu-Chou Su, Te-Chun Hsia, Jiuwei Cui, Yuping Sun, James Chih-Hsin Yang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT190.
https://doi.org/10.1158/1538-7445.AM2020-CT190
Published: 15 August 2020
View articletitled, Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)